Anavex Life Sciences Corp.AVXLNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year operating income growth rate
Latest
-15.55%
↓ 40% below average
Average (39q)
-11.09%
Historical baseline
Range
High:52.41%
Low:-186.96%
CAGR
-5.8%
Structural decline
| Period | Value |
|---|---|
| Q2 2025 | -15.55% |
| Q1 2025 | 7.94% |
| Q4 2024 | 5.19% |
| Q3 2024 | 2.67% |
| Q2 2024 | -16.67% |
| Q1 2024 | -10.95% |
| Q4 2023 | 10.07% |
| Q3 2023 | 6.50% |
| Q2 2023 | 4.64% |
| Q1 2023 | 7.61% |
| Q4 2022 | -0.49% |
| Q3 2022 | -22.67% |
| Q2 2022 | -8.15% |
| Q1 2022 | 1.73% |
| Q4 2021 | 4.32% |
| Q3 2021 | -7.90% |
| Q2 2021 | -26.96% |
| Q1 2021 | 4.81% |
| Q4 2020 | -21.38% |
| Q3 2020 | 4.50% |
| Q2 2020 | -5.30% |
| Q1 2020 | -0.94% |
| Q4 2019 | -21.61% |
| Q3 2019 | 12.26% |
| Q2 2019 | 12.20% |
| Q1 2019 | -10.01% |
| Q4 2018 | -22.50% |
| Q3 2018 | -30.79% |
| Q2 2018 | 2.45% |
| Q1 2018 | -15.69% |
| Q4 2017 | 20.97% |
| Q3 2017 | -39.76% |
| Q2 2017 | -3.15% |
| Q1 2017 | -14.65% |
| Q4 2016 | 52.41% |
| Q3 2016 | -186.96% |
| Q2 2016 | -5.23% |
| Q1 2016 | 44.42% |
| Q4 2015 | 1.13% |
| Q3 2015 | -162.19% |